News Releases

May 05, 2022
Lyra Therapeutics to Present at Upcoming Investor Conferences
WATERTOWN, Mass. , May 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased
Additional Formats
Apr 21, 2022
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit of LYR-210 to Chronic Rhinosinusitis Patients WATERTOWN, Mass. , April 21, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc.
Additional Formats
Apr 08, 2022
Lyra Therapeutics Announces $100.5 Million Private Placement
WATERTOWN, Mass. , April 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting
Additional Formats
Mar 07, 2022
Lyra Therapeutics Appoints Jim Tobin to Board of Directors
Biopharmaceutical leader brings decades of expertise with C-suite tenures at Boston Scientific, Biogen and Baxter International WATERTOWN, Mass. , March 7, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform
Additional Formats
Displaying 1 - 10 of 12
Print Page
Email Alerts
RSS Feeds
Contact IR
Search
Back to Top